Paving the way to efficient and sustainable future of adherent cell cultivation -
for people
and the planet.
Healthy people: Enabling patient access
New therapies become approved in a fast-paced manner, but how accessible are these to patients?
Cell and Gene Therapy (CGT) costs up to $4.25 m per dose.¹ A price tag that most patients are not able to cover themselves or to be paid by their health insurances. Advanced therapies are therefore not accessible for everyone.
In Cell & Gene Therapy, manual labor causes up to 71% of production costs.² Manufacturing therapies includes a complex and intensive cell cultivation process.
Innovating scalable systems for adherent cell culture, like the CellScrew®, are key to increasing patient access and affordability to life-changing novel therapies.
400 million people are affected by rare diseases³
2x more approved therapies since 2013 in the Cell and Gene Therapies sector⁴
57% increase in manufacturing skills demand until 2028⁵ and expectations for capacity constraints⁶
Healthy planet: Cutting carbon emissions
Healthy people need a healthy planet. Aiming to help people and treat diseases, the healthcare sector produces 55% more greenhouse gas (GHG) emissions than the automotive industry.⁷
The industry produces massive amounts of plastic waste and accounts for 4.4% of the global net carbon emissions⁸, harming the environment we live in and rely on. More than ever before, it is obvious that limiting temperature rise by reducing emissions is essential for preventing further damage to the health of our planet and ourselves.
How can we reduce the impact of our healthcare system?
Being the pioneering company for the production of labware from plant-based plastic, we empower the biopharmaceutical industry to embrace sustainability.
4.4 % of global net emissions are caused by the healthcare sector⁸
5.5 million tons of lab plastic waste is produced annually⁹
4.2 million premature deaths estimated to be caused by ambient air pollution worldwide in 2019¹⁰
Our contribution to the Sustainable Development Goals
A seamless pipeline from biopharma research and development to manufacturing is crucial in delivering life-saving treatments to patients cost-effectively and within a short time-to-market.
Our CellScrew® product is built on the idea of empowering the biopharmaceutical industry to operate more sustainably and efficiently. With our innovative solutions, we aim to overcome the challenge of limited production capacity in the biopharmaceutical sector by introducing an easily adoptable cell culture system that maximizes productivity.
Hear about our vision in one of these videos
Company Updates
